下一代 aGile 试验以胶质母细胞瘤为靶点，使用参与者的 DNA 进行个性化治疗。 Next-Generation aGile trial targets glioblastoma, personalizing treatments with participants' DNA.
研究人员发起了一项开创性试验,旨在改造脑癌治疗,特别是针对血浆瘤的治疗。 Researchers have launched a pioneering trial designed to transform brain cancer treatment, specifically targeting glioblastoma. “下一代 aGile 基因组指导的神经胶质瘤平台试验”将使用参与者的 DNA 根据他们的基因图谱定制治疗。 The "next-Generation aGile Genomically Guided Glioma platform trial" will use participants’ DNA to tailor treatments based on their genetic profiles. 这次试验由英国癌症研究基金会和明德鲁基金会资助,将允许快速检测各种药物,包括为其他癌症研制的药物,标志着脑癌治疗取得显著进展。 Funded by Cancer Research UK and Minderoo Foundation, the trial will allow for rapid testing of various drugs, including those developed for other cancers, marking a significant advancement in brain cancer therapy.